Guidelines for the use of Binimetinib
Binimetinib is an oral MEK1/MEK2 kinase inhibitor that needs to be used in combination with Conafenib. It is mainly used to treat BRAFV600E/K mutation positive melanoma and non-small cell lung cancer. The following provides a detailed explanation of the medication guidelines from the aspects of usage, dosage adjustment, medication for special populations, and precautions.
1. Usage and dosage
(1) Adult metastatic melanoma: In combination with Conafenib, take 45 milligrams orally every 12 hours until disease progression or unacceptable toxic reactions occur.
(2) Non small cell lung cancer: also using a combination therapy, 45 milligrams each time, once every 12 hours, continuously taking medication until disease progression or intolerance occurs.
2 dose adjustments
(1) First dose reduction: If the dose needs to be adjusted, it can be changed to 30 milligrams per dose, once every 12 hours.
(2) Permanent discontinuation criteria: If the 30mg dose cannot be tolerated, or if Kenafenib is permanently discontinued, Bimetinib must be discontinued.
(3) Liver dysfunction: The recommended dose for moderate or severe damage is 30 milligrams per dose, twice a day; Mild damage does not require adjustment.
3. Medication for special populations
(1) Pregnancy: May cause harm to the fetus, should be avoided.
(2) Breastfeeding period: Breastfeeding should be stopped during the treatment period and within 3 days after the last dose.
(3) Children: Safety and efficacy have not yet been established.
(4) Elderly people: There is no significant difference in efficacy compared to young adults.
4 Precautions
(1) Missing service handling: If missed, it needs to be replenished as soon as possible; If it is less than 6 hours before the next medication, skip and double the dosage is prohibited.
(2) Contraceptive requirements: Women of childbearing age must take effective contraceptive measures during treatment and within 30 days after the last dose.
(3) Drug overdose: There is currently no clear treatment plan and close monitoring is required.
Disclaimer：《Guidelines for the use of Binimetinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！